CRSP vs VRTX
CRSP and VRTX side by side — valuation & fundamentals (public data).
Key statistics
| Metric | CRSPCRISPR THERAPEUTICS AG | VRTXVERTEX PHARMACEUTICALS INC / MA |
|---|---|---|
| Market cap | $4.59B | $122.73B |
| P/E (TTM) | — | 28.7 |
| P/B | — | 6.34 |
| P/S | 1307.1x | 10.4x |
| Revenue | — | $12.22B(TTM) |
| Revenue growth (YoY) | -90.6% | 8.9% |
| Net income | — | $4.34B(TTM) |
| Earnings growth (YoY) | -58.8% | 838.1% |
| EPS, diluted | — | $16.85(TTM) |
| EBIT margin | -18933.6% | 34.8% |
| ROE | -32.1% | 20.4% |
| ROIC | -33.6% | 25.4% |
| 1y total return | -19.4% | +4.6% |
Figures from SEC filings · for reference only · not investment advice
Growth of $10,000: CRSP vs VRTX
| Metric | CRSP | VRTX |
|---|---|---|
| End value | $33.8K | $59.1K |
| Total return | +238.1% | +490.6% |
| CAGR | +13.3% | +19.9% |
| Volatility | 64.2% | 32.7% |
| Sharpe | 0.45 | 0.60 |
| Sortino | 0.70 | 0.89 |
| Max drawdown | -85.1% | -41.6% |
Based on 2456 common trading days, 2016-10-19 → 2026-07-29 · risk-free 3.83% (current short-Treasury, held constant)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)